Dr Reddy’s launches Supamove cream for pain management in India

Our Bureau, MumbaiThursday, December 29, 2011, 13:50 Hrs  [IST]

Dr Reddy’s Laboratories has  launched Supamove cream. It helps to reduce pain and inflammation in patients with joint pain, arthritis, bursitis, tendinitis and lower back pain. The product has been in-licensed from Cymbiotics Inc. USA and will be available in a 30 gm tube. Other brands of Dr Reddy’s in that segment include Supanac– oral NSAID and Ruffy- injectable opioid.
Dr. Reddy’s also strengthened its emollients and protective product portfolio with the launch of venusia soft lotion. It provides sustained relief from dry, itchy skin (Pruritis) and will complete Dr Reddy’s treatment basket in the emollient and protective space which already includes venusia cream, venusia lotion, venusia max and venusia bathing bar. venusia soft lotion is in-licensed from Cymbiotics Inc. USA and will be available in a 75 ml pack.

The current market size of topical NSAID segment in India is over Rs. 352 crore with an annual growth rate of 18 per cent (ORG IMS MAT Mar 2011). Other leading brands of Dr Reddy’s in the topical NSAID segment are Nise gel and Celadrin cream. The emollients and protectives market in India is currently valued at Rs. 208 crore growing at over 18 per cent  annually (ORG-IMS). Dr Reddy’s has in the past licensed three other products from Cymbiotics Inc. - Celadrin, Ezinapi and GLA-AD.
Based in San Diego, California, USA , Cymbiotics, Inc. is a bio-pharmaceutical company that designs, develops, validates and introduces innovative disease-specific formulations in pain management and other inflammatory diseases, dermatology, urology and other therapeutic areas.